Partner Randy D. Gordon, chair of the Firm’s antitrust and trade regulation practice, authored an article for Law360 regarding the merger between Anheuser-Busch InBev and its rival SAB Miller.
“The antitrust and related regulatory issues with this merger are legion,” said Mr. Gordon. “The first question many antitrust lawyers ask themselves when setting down to analyze the ramifications of any proposed transaction is, ‘Who’s going to complain?’ Here, the answer is, ‘Lots of people.’”
Subscribers can access the full article here.
Related Insights
06 November 2024
November 2024 Midwest Cyber Security Alliance Meeting | Resilience Awakens: Tapping Into Your Inner Force for Managing Stress Effectively
Join us on Wednesday, November 20, 2024, for a very special Midwest Cyber Security Alliance meeting offering a unique, interactive approach to mental wellness, helping professionals thrive in high-stress environments like cybersecurity.
12 November 2024
Events
MEMA Original Equipment Suppliers Annual Conference 2024
Join Foley at the MEMA Original Equipment Suppliers Annual Conference on November 12-13.
05 November 2024
Health Care Law Today
Cancer Drugs: Clinical Trial Issues for Antibody Drug Conjugates (ADCs)/Antibody Therapeutics
Antibody Drug Conjugates (ADCs) are a class of small molecule drugs and an antibody conjugated together by a chemical linker.